Search In this Thesis
   Search In this Thesis  
العنوان
Sugammadex versus neostigmine in the reversal of neuromuscular block in pediatric patients undergoing thoracic surgery /
المؤلف
Elgazar, Manal Abdel Fattah.
هيئة الاعداد
باحث / منال عبد الفتاح الجزار
مشرف / خالد موسى ابو العنين
مشرف / عصام عبد الحميد غنيم
مشرف / زينب عبد العزيز قاسمي
الموضوع
Anesthesiology.
تاريخ النشر
2019.
عدد الصفحات
79 P. :
اللغة
الإنجليزية
الدرجة
ماجستير
التخصص
التخدير و علاج الألم
تاريخ الإجازة
22/7/2019
مكان الإجازة
جامعة المنوفية - كلية الطب - التخدير
الفهرس
Only 14 pages are availabe for public view

from 110

from 110

Abstract

Muscle relaxants are routinely used worldwide as a part of a modern concept of balanced anesthesia. They can be categorized as depolarizing (eg, succinylcholine) and nondepolarizing (steroid-based and benzylisoquinoline) muscle relaxants. Although nondepolarizing muscle relaxants have very few adverse effects (mostly allergic reactions) during anesthesia, a residual duration of action of muscle relaxants beyond the end of the operation, also referred to as postoperative residual curarization (PORC) is a well-known problem.
Acetylcholinestrase inhibitors may cause postoperative residual curarization when they are used for reversal of neuromuscular blockade. Sugammadex reverses neuromuscular blockade by chemical encapsulation and is not associated with the side effects that may occur with the use of anticholinesterase agents. Because of increased pediatric thoracic surgical procedures postoperative residual curaization and rapid postoperative recovery have a greater importance.
Aim: The aim of this study was to compare the efficacy of sugammadex and neostigmine on reversing neuromuscular blockade in pediatric patients undergoing thoracic surgical procedures.
Patient and methods: Sixty healthy pediatric patients ASA I or II scheduled for thoracic surgery were enrolled in this study. They were randomly divided into two equal groups (thirty patients each) to receive sugammadex (group S), neostigmine (group N) as a reversal drug for rocuronium at the end of surgery. In group S only 27 patients